Reuters logo
BRIEF-Ligand enters into worldwide Omniab platform license agreement with Surface Oncology
June 1, 2017 / 1:24 PM / 4 months ago

BRIEF-Ligand enters into worldwide Omniab platform license agreement with Surface Oncology

June 1 (Reuters) - Ligand Pharmaceuticals Inc

* Ligand enters into worldwide Omniab® platform license agreement with Surface Oncology

* Has entered into a worldwide license agreement with Surface Oncology

* Ligand Pharmaceuticals - under license, Surface will use omnirat, omnimouse, omniflic platforms to discover fully human mono- and bispecific antibodies

* Surface will be responsible for all costs related to programs Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below